Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

NCT07566585 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

AML - Acute Myeloid Leukemia
AML With Mutated NPM1
AML, Adult Recurrent

Interventions

DRUG: SOC+ BSB-2002
DRUG: SOC+BSB-2002

Sponsor

BlueSphere Bio, Inc